A Clinical Trial to Test the Effect of Experimental Mouth Rinse on Gum Disease

At screening Participants will present to the clinical site having refrained from oral hygiene for at least 8 hours, but no more than 18 hours for baseline examinations (safety oral and hard soft tissue exam, MGI - Modified Gingival Index, BI - Bleeding Index and PI- Plaque Index and Extrinsic Staining. After the baseline oral examinations, qualifying participants will receive a whole-mouth supragingival dental prophylaxis and will be randomly assigned to one of three treatment groups.

Participants randomly assigned to the negative control treatment group will brush twice daily with a marketed fluoride toothpaste in their usual manner and rinse with a placebo mouth rinse. Participants randomly assigned to the experimental treatment group will brush twice daily with a marketed fluoride toothpaste brush in their usual manner and use an experimental mouth rinse. The last treatment group randomly assigned to the positive control will brush twice daily with a marketed fluoride toothpaste in their usual manner and rinse with a marketed available mouth rinse. Participants will have an equal chance of being assigned each of the three groups. The first product use will be conducted under supervision of study personnel. Participants will be required to stay at the site 20 minutes after the first use of product during visit 1 to monitor any potential analytic reaction. All other brushing and rinsing will be unsupervised and the participants will be required to maintain a diary card to document twice-daily product use, brushing and rinsing times. Diaries along with product accountability will be used to check for subject compliance.

Participants will return to the clinical site after 1 week (Day 7±1 day), 2 weeks (Day 14±2 days) and 4 weeks (Day 28±3 days). Oral hard and soft tissue safety, Modified Gingival Index (MGI), Bleeding Index (BI), and Plaque Index (PI) will be assessed by the primary examiner 1 at all visits Extrinsic stain will be assessed at baseline, 2 weeks and 4 weeks by the secondary examiner.

At the end of the study, subjects will return all used and unused product to the clinical site.

Inclusion criteria

• 1. Males and females 18 years of age or older, in good general and oral health without any known allergy to commercial dental products or cosmetics.
• 2. Evidence of a personally signed and dated informed consent document indicating the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial and all questions have been answered.
• 3. Females of childbearing potential must be using a medically-acceptable method of birth control for at least 1 month prior to Visit 1 and agree to continue using this method during their participation in the study.
• 4. Able to comprehend and follow the requirements of the study (including availability on scheduled visit dates) based upon research site personnel's assessment.
• 5. A minimum of 20 natural teeth with scorable facial and lingual surfaces. Teeth that are grossly carious, extensively restored, orthodontically banded, abutments, exhibiting severe generalized cervical and/or enamel abrasion, or third molars will not be included in the tooth count.
• 6. A mean gingival index ≥1.75 according to the Modified Gingival Index.
• 7. A mean plaque index ≥1.95 according to the Turesky modification of the Quigley-Hein Plaque Index scored on six surfaces per tooth.
• 8. Mean Bleeding Index ≥0.15
• 9. Absence of significant oral soft tissue pathology, excluding plaque-induced gingivitis, based on a visual examination and at the discretion of the Investigator.
• 10. Absence of moderate/advanced periodontitis based on a clinical examination (ADA Type III, IV).
• 11. Absence of fixed or removable orthodontic appliance or removable partial dentures.

Exclusion criteria

• 1. History of significant adverse effects, including sensitivities or suspected allergies, following use of oral hygiene products such as toothpastes and mouth rinses and red food dye.
• 2. Dental prophylaxis within 2 weeks prior to Screening visit.
• 3. History of medical conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures.
• 4. Antibiotic, anti-inflammatory or anticoagulant therapy during the study or within the one month prior to the baseline exam. Intermittent use of certain anti-inflammatory medication is acceptable at the discretion of the investigator.
• 5. Daily use of aspirin.
• 6. Known sensitivity to the investigational product ingredients.
• 7. Self reported pregnancy or lactation (this criterion is due to oral tissue changes related to pregnancy and nursing which can affect interpretation of study results).
• 8. Significant unstable or uncontrolled medical condition which may interfere with a subject's participation in the study, at the discretion of the Investigator.
• 9. Participation in any clinical study within 30 days of Visit 1.
• 10. Relative, partner or staff of any clinical research site personnel.
• 11. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.